Literature DB >> 25101859

Phosphodiesterase 4 interacts with the 5-HT4(b) receptor to regulate cAMP signaling.

S Weninger1, K Van Craenenbroeck2, R T Cameron3, F Vandeput4, M A Movsesian4, G S Baillie3, R A Lefebvre5.   

Abstract

Phosphodiesterase (PDE) 3 and PDE4, which degrade cyclic adenosine monophosphate (cAMP), are important regulators of 5-hydroxytryptamine (5-HT) 4 receptor signaling in cardiac tissue. Therefore, we investigated whether they interact with the 5-HT4(b) receptor, and whether A-kinase anchoring proteins (AKAPs), scaffolding proteins that bind to the regulatory subunit of protein kinase A (PKA) and contribute to the spacial-temporal control of cAMP signaling, are involved in the regulation of 5-HT4(b) receptor signaling. By measuring PKA activity in the absence and presence of PDE3 and PDE4 inhibitiors, we found that constitutive signaling of the overexpressed HA-tagged 5-HT4(b) receptor in HEK293 cells is regulated predominantly by PDE4, with a secondary role for PDE3 that is unmasked in the presence of PDE4 inhibition. Overexpressed PDE4D3 and PDE3A1, and to a smaller extent PDE4D5 co-immunoprecipitate constitutively with the 5-HT4(b) receptor. PDE activity measurements in immunoprecipitates of the 5-HT4(b) receptor confirm the association of PDE4D3 with the receptor and provide evidence that the activity of this PDE may be increased upon receptor stimulation with 5-HT. A possible involvement of AKAPs in 5-HT4(b) receptor signaling was uncovered in experiments using the St-Ht31 inhibitor peptide, which disrupts the interaction of AKAPs with PKA. However, St-Ht31 did not influence 5-HT4(b) receptor-stimulated PKA activity, and endogenous AKAP79 and gravin were not found in immunoprecipitates of the 5-HT4(b) receptor. In conclusion, we found that both PDE3A1 and PDE4D3 are integrated into complexes that contain the 5-HT4(b) receptor and may thereby regulate 5-HT4(b) receptor-mediated signaling.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  5-HT(4) receptor signaling; PDE3A1; PDE3A2; PDE3B; PDE4D3; PDE4D5

Mesh:

Substances:

Year:  2014        PMID: 25101859     DOI: 10.1016/j.cellsig.2014.07.027

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  5 in total

1.  Role of cAMP/PKA pathway and T-type calcium channels in the mechanism of action of serotonin in human adrenocortical cells.

Authors:  Estelle Louiset; Céline Duparc; Sébastien Lenglet; Celso E Gomez-Sanchez; Hervé Lefebvre
Journal:  Mol Cell Endocrinol       Date:  2016-10-12       Impact factor: 4.102

2.  Regulation of sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) activity by phosphodiesterase 3A (PDE3A) in human myocardium: phosphorylation-dependent interaction of PDE3A1 with SERCA2.

Authors:  Faiyaz Ahmad; Weixing Shen; Fabrice Vandeput; Nicolas Szabo-Fresnais; Judith Krall; Eva Degerman; Frank Goetz; Enno Klussmann; Matthew Movsesian; Vincent Manganiello
Journal:  J Biol Chem       Date:  2015-01-15       Impact factor: 5.157

3.  Which phosphodiesterase can decrease cardiac effects of 5-HT4 receptor activation in transgenic mice?

Authors:  Joachim Neumann; Benedikt Käufler; Ulrich Gergs
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-04-24       Impact factor: 3.000

4.  Synthesis and Modeling Studies of Furoxan Coupled Spiro-Isoquinolino Piperidine Derivatives as NO Releasing PDE 5 Inhibitors.

Authors:  Swami Prabhuling; Yasinalli Tamboli; Prafulla B Choudhari; Manish S Bhatia; Tapan Kumar Mohanta; Ahmed Al-Harrasi; Zubaidha K Pudukulathan
Journal:  Biomedicines       Date:  2020-05-14

Review 5.  Functions of PDE3 Isoforms in Cardiac Muscle.

Authors:  Matthew Movsesian; Faiyaz Ahmad; Emilio Hirsch
Journal:  J Cardiovasc Dev Dis       Date:  2018-02-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.